Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming

J Intern Med. 2021 Dec;290(6):1272-1274. doi: 10.1111/joim.13366. Epub 2021 Aug 2.
No abstract available

Keywords: BNT162b2; COVID-19; IgA; IgG; IgM; RBD; SARS-CoV-2; antibody neutralization; antibody response; immunoassays; nucleocapsid protein; serology; vaccine.

Publication types

  • Letter

MeSH terms

  • Antibodies, Neutralizing*
  • Antibodies, Viral / immunology*
  • Antibody Formation
  • BNT162 Vaccine
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / genetics
  • COVID-19 Vaccines / immunology*
  • Denmark
  • Health Personnel
  • Humans
  • Immunogenicity, Vaccine
  • Immunoglobulin G / immunology
  • RNA, Messenger / administration & dosage
  • RNA, Messenger / genetics
  • RNA, Messenger / immunology*
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • RNA, Messenger
  • BNT162 Vaccine